Improving lives with innovative technology is the common goal of circumnavigator Adrian Bleninger, NanoTemper and SIRION Biotech. Both NanoTemper and SIRION Biotech provide their advanced technologies to the world’s leading pharmaceutical and academic researchers developing next-generation therapies. For Adrian Bleninger, the race is not just about human performance and resilience, but also about pushing new technologies to the limit. He will build his state-of-the-art boat with recyclable and resource-saving materials and plans to raise awareness about the poor state of the ocean through his “Happy Ocean Project.”

With a successful campaign for the Vendée Globe, Adrian Bleninger could become the second German citizen to ever participate. He would also represent Germany as one of the world’s leading technology locations. Adrian is not only looking forward to wearing this award, but he is also ready for the challenge of a race in which participants spend around 80 days alone at sea. Professionally, he has become a boat builder on the North and Baltic Seas. When he is not ferrying yachts between continents, he participates in world-renowned sailing regattas.

NanoTemper and SIRION Biotech invite other Bavarian and German technology companies to support Adrian Bleninger’s application. Sponsorship provides visibility across a wide range of media in a race that challenges today’s technological and human limits. Here’s more info on how to support dedicated sailor Adrian Bleninger: https://adrianbleningerracing.com/

NanoTemper’s mission is to give everyone the opportunity to do science that matters by continually pushing the envelope. Founded in 2008, NanoTemper focuses on making tools that enable sophisticated characterization for use in drug discovery and basic research – especially for researchers facing challenges in affinity screening, molecular interactions, protein stability or protein quality. The company now has over 150 employees in 13 countries.

Founded in 2007, SIRION Biotech is a leading commercial provider of advanced viral vector technologies (AAV, LV, AV) and transduction reagents to academic and commercial partners around the world. Its commitment to research combined with its intimate knowledge of viral vectors enables SIRION Biotech to develop new generations of optimized vectors for use in gene and cell therapy. The company employs more than 45 people worldwide and has sites in the Innovation and Start-up Center (IZB) in Martinsried by Munich as well as in Boston and Paris.